<DOC>
	<DOC>NCT02172573</DOC>
	<brief_summary>The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).</brief_summary>
	<brief_title>Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism) Patients who meet all of the following inclusion criteria Patients who were at least 20 years of age In or outpatients of either sex Patients in any stage on the modified Hoehn and Yahr scale Patients being treated with Ldopa who have any of the following clinical conditions and problems Patients with the wearingoff phenomenon Patients with the onoff phenomenon Patients to whom a sufficient amount of Ldopa cannot be administered owing to the occurrence of an adverse event Patients in whom the effect of Ldopa is attenuated Patients in whom a dose increase of Ldopa has been refrained Patients with freezing phenomenon Patients being treated with other dopamine agonists (bromocriptine, pergolide mesylate, talipexole hydrochloride). Patients who have been treated with other dopamine agonist for at least 4 weeks before the start of the study (the day of giving informed consent) are eligible for the study Patients with a history of hypersensitivity to ergot preparations Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour Patients with subjective symptoms derived from orthostatic hypotension Patients with hypotension (systolic blood pressure less than 100 mmHg) Patients wiht Raynaud disease Patients with peptic ulcer Patients with complications such as severe cardiac, renal, hepatic disease etc. Patients with a current or past history of epilepsy Women who are or may be pregnant and lactating women Patients who are receiving any other investigational products or who have received any other investigational product within 6 months of the study Patients who are incompetent to give consent Others judged by the investigator or coinvestigator to be ineligible as subjects</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>